Streetbeat News

TRML

Tourmaline Bio, Inc.

https://www.tourmalinebio.com

Industry

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Open

22.69

Mkt cap

590M

Volume

284K

High

23.59

P/E Ratio

-9.24

52-wk high

48.31

Low

22.21

Div yield

N/A

52-wk low

12.12

Tourmaline Bio, Inc. (NASDAQ: TRML) will host a virtual Investor Day on December 10, 2024, featuring presentations from its leadership and Dr. Marc Bonaca. The event aims to provide insights into the company's progress in developing medicines for immune and inflammatory diseases.

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Tourmaline Bio, Inc. reported its Q3 2024 financial results, highlighting a cash position of $314.4 million, which extends its runway into 2027. The company is on track to release Phase 2 trial data in 2025 and has formed a Cardiovascular Scientific Advisory Board.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:31 am

Tourmaline Bio (NASDAQ:TRML) reported a Q2 2024 adjusted EPS of $(0.68), beating the analyst consensus estimate of $(0.71) by 4.23%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:51 pm

Tourmaline Bio, Inc. (NASDAQ: TRML) presented the design of its Phase 2 TRANQUILITY study at the ASPC Congress 2024. The study evaluates the effects of TOUR006 on hs-CRP levels in CKD patients. Topline data is expected in the first half of 2025, potentially advancing TOUR006 to Phase 3 for ASCVD and other cardiovascular diseases.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 8:31 pm

Tourmaline Bio has appointed Ryan Robinson as the new Chief Financial Officer, effective June 25.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:06 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $48 price target.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 1:57 pm

Tourmaline Bio reported ending the first quarter with $350.3 million in cash, cash equivalents, and investments, extending its cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:19 am

Tourmaline Bio reported its Q1 2024 GAAP earnings per share (EPS) at $(0.55), surpassing the estimated $(0.66).

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:18 am

Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a $74 price target.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.